BioPharma-Reporter » Biosimilars
184 FOLLOWERS
Take a peek into the news on the biopharmaceutical manufacturing industry, focusing on biologics, biosimilars, technology, upstream/downstream processing, cell culture, and regulations. William Reed's BioPharma-Reporter has been the leading online news source for the biopharma industry for more than 8 years, leveraging our digital-first position to bring powerful insights and robust..
BioPharma-Reporter » Biosimilars
3d ago
In a recent interview, Hayley Crowe, head of Ecolab's global life sciences business, shed light on Purolite's latest developments and its significant contributions to the biopharmaceutical industry ..read more
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
BioPharma-Reporter » Biosimilars
4d ago
Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients ..read more
BioPharma-Reporter » Biosimilars
4d ago
UK-based biotech Glen Clova Scientific has raised Â4 million in seed financing to develop a pipeline of a new generation of active biologic drugs ..read more
BioPharma-Reporter » Biosimilars
4d ago
A recent Deloitte report revealed that 36% of healthcare product launches fell short of achieving 80% of their sales targets within the first two years ..read more
BioPharma-Reporter » Biosimilars
4d ago
From a child's chemistry set given to her by her grandfather to watching Open University maths programs, Karen Ooms seemed destined for a career in science ..read more
BioPharma-Reporter » Biosimilars
6d ago
CN Bio has raised $21 million in Series B financing to meet increasing demand for its organ-on-a-chip (OOC) solutions ..read more
BioPharma-Reporter » Biosimilars
6d ago
Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) version of Entyvio, its treatment for adults with moderate to severe Crohnâs disease (CD ..read more
BioPharma-Reporter » Biosimilars
6d ago
Celularity, a biotech company specializing in placental-derived allogeneic cell therapies, will be showcasing data at the upcoming ASGCT Annual Meeting, showcasing the potential of their off-the-shelf natural killer (NK) cells to combat age-related diseases ..read more
BioPharma-Reporter » Biosimilars
6d ago
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US ..read more
BioPharma-Reporter » Biosimilars
1w ago
After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers ..read more